Obesity wonder drugs Wegovy and Zepbound are already showing that they can reduce the risk of cardiovascular and chronic kidney disease in addition to helping people lose weight. Now, a US-wide trial will test whether tirzepatide, the active ingredient in Zepbound, may be an effective treatment for people with long Covid.
Part of a class of drugs known as GLP-1s, tirzepatide acts on receptors in the gut and the brain to regulate appetite. As a result, people shed pounds by eating less. But decreased body weight doesn’t fully explain the positive effects on the heart and kidney. Mounting evidence suggests that the drugs have a
Read More